At a glance

A biotech company focusing on transformative RNA-based treatments by developing novel drug candidates targeting major splicing mutations in genetic diseases. Splisense pioneering platform harnesses Antisense Oligonucleotides (ASOs) for treatment of genetic diseases such as Cystic Fibrosis and other pulmonary diseases.

Investors

Integra Holdings, Orbimed. Israel Biotech Fund, Cystic Fibrosis, Foundation